Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 05/03 10:00:00 pm
156.35 USD   -1.66%
05/03 AMGEN : FDA Grants Priority Review For Amgen's Supplemental Biologic..
04/28 AMGEN : beats Street 1Q forecasts
04/28DJAmgen Profit Rises 17%, Guidance Raised
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on AMGEN, INC.
05/03 AMGEN : FDA Grants Priority Review For Amgen's Supplemental Biologics License Ap..
05/02 AMGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
04/28 AMGEN INC : Results of Operations and Financial Condition, Financial Statements ..
04/28 AMGEN : beats Street 1Q forecasts
04/28DJAmgen Profit Rises 17%, Guidance Raised
04/28 AMGEN : posts 1Q sales, profit jumps, raises profit forecasts
04/28 AMGEN : 's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And ..
04/28DJAmgen Profit Rises 17%, Guidance Raised--Update
04/28DJAmgen Profit Rises 17%, Guidance Raised
04/28 CYTOKINETICS : Reports First Quarter 2016 Financial Results
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials